News | February 19, 2022
Natco Q3FY22 PAT up 27% to Rs 80 Cr
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
The entire integration and transition of the brands is expected to be completed by March 2022
Key takeaways of Q3FY22 quarter & conference call highlights
The KRIVIDA Novus RT-PCR kit can detect the Omicron variant, its sub-lineages, and the Delta variant in 45 minutes
Key takeaways of recent quarter & conference call highlights
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Key takeaways of recent quarter & conference call highlights
Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
Subscribe To Our Newsletter & Stay Updated
